Lung Adenocarcinoma (LUAD) Discoveries from two NCI Proteomics Consortia NCI, July 9, 2020

Hot Topics of the Day|PHGKB


Last Posted: Jul 10, 2020

---

• Lung Adenocarcinoma (LUAD) Discoveries from two NCI Proteomics Consortia
  NCI, July 9, 2020
• Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience.
  El Osta Badi et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2019 14(5) 876-889
• Circulating biomarkers predictive of tumor response to cancer immunotherapy.
  Lee Ernest Y et al. Expert review of molecular diagnostics 2019 19(10) 895-904
• Clinical implications of circulating cell-free DNA quantification and metabolic tumor burden in advanced non-small cell lung cancer.
  Hyun Myung Han et al. Lung cancer (Amsterdam, Netherlands) 2019 134158-166
• Evaluation, Validation, and Implementation of the Idylla System as Rapid Molecular Testing for Precision Medicine.
  Huang Huiya et al. The Journal of molecular diagnostics : JMD 2019 21(5) 862-872
• Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing.
  Kim Hong Sook et al. European journal of cancer (Oxford, England : 1990) 2019 12065-74
• Integrating genetic mutations and expression profiles for survival prediction of lung adenocarcinoma.
  Song Yueqiang et al. Thoracic cancer 2019 10(5) 1220-1228
• Clinical Utility of Reflex Ordered Testing for Molecular Biomarkers in Lung Adenocarcinoma.
  Anand Kartik et al. Clinical lung cancer 2020 May
• Costs of in-house genomic profiling and implications for economic evaluation: A case example of non-small cell lung cancer (NSCLC).
  Johnston Karissa M et al. Journal of medical economics 2020 Jun 1
• Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer.
  Schatz Stefanie et al. Cancers 2020 Jun 12(6)

more